MedTrace Logo

Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB

NCT05063110 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-12-26

No results posted yet for this study

Summary

This project aims to test the effectiveness of ITACITINIB in sporadic Hemophagocytosis Lymphohistiocytosis (HLHs)

Conditions

  • Adults Patients Having Non Severe HLH

Interventions

DRUG

Itacitinib

Administration of 300 mg of ITACITINIB per os every day for 30 days.

Sponsors & Collaborators

  • Incyte Corporation

    collaborator INDUSTRY

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-03
Primary Completion
2025-04-03
Completion
2025-10-01

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05063110 on ClinicalTrials.gov